Category: Press Release

Download PDF – Cumulative data of three Phase 3 studies demonstrate greater exposure of tivozanib is associated with increased clinical benefit ––  Patient Reported Outcomes were numerically better for patients receiving tivozanib in a second line setting versus third line – BOSTON, Feb. 18, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is

Download PDF BOSTON, Feb. 12, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, announced today two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) 2025 meeting this February 13-15, 2025, in San

Download PDF – TiNivo-2 FOTIVDA® (tivozanib) monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line immune checkpoint inhibitor (ICI) combinations – – TIVO-3 Exploratory Overall Survival (OS) Analysis Provides Additional Data for FOTIVDA Following Immunotherapy – – Safety results support the well-established safety profile of FOTIVDA – BOSTON, September 16, 2024

Download PDF BOSTON, September 3, 2024 (PR Newswire) – AVEO Oncology, an LG Chem company (“AVEO”), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain this September 13-17th. The oral presentation

Download PDF – The addition of nivolumab to low dose tivozanib after prior immune checkpoint inhibitor (ICI) is not superior to standard dose tivozanib alone; as a result, the primary endpoint was not met – – Tivozanib monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line ICI combinations – – Safety

Download PDF – LG Chem to embark on developing Next-Generation Immune Checkpoint Inhibitors to Provide Solid Tumor Treatment Solutions – – LG Chem and AVEO Oncology continuing to advance its shared vision of becoming a leading global oncology company – BOSTON, June 13, 2024 (PR Newswire) — LG Chem and AVEO Oncology, an LG Chem

Download PDF – Industry veteran brings extensive clinical development experience to AVEO Oncology leadershipteam as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 28, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in

Download PDF BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) — AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma

Download PDF BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or

Download PDF Boston, MA (November 30, 2023) — For the second year in a row, AVEO Oncology, an LG Chem company, has earned a spot on the Boston Globe’s annual ‘Top Places to Work in Massachusetts’ list.  AVEO Oncology appears in the medium-sized company (100-249 employees) category. “We are incredibly excited to be selected once